US Patent 9,283,178: Claim Scope, Dexamethasone Implant Coverage, Expiry Risk, and Patent Landscape

US Patent 9,283,178 covers a method of treating ocular edema by placing a bioerodible intraocular delivery system containing an immunosuppressive agent at a high drug-loading level of about 50% to 80% by weight. The dependent claims narrow the invention to vitreous placement, PLGA polymers, delivery lasting at least five days or about three weeks, and dexamethasone.

The claims are method-of-treatment claims, not broad composition claims. Their commercial relevance is strongest for biodegradable intravitreal steroid implants, including products using dexamethasone and PLGA. The principal infringement issue is whether a marketed implant satisfies the 50%-80% drug-loading limitation and the claimed treatment method.

What does US Patent 9,283,178 claim?

Claim 1 requires every element below:

Claim element	Scope
Patient and condition	An individual with edema in an eye
Intervention	Placement of a bioerodible drug-delivery system in the eye
Active agent	An immunosuppressive agent
Matrix	A bioerodible polymer
Drug loading	Immunosuppressive agent comprises about 50% to about 80% by weight of the total system
Result	Treatment of ocular edema

The claim does not require a particular edema subtype. It potentially reaches macular edema, diabetic macular edema, retinal vein occlusion-associated edema, postoperative edema, and other forms of ocular edema, provided the claimed delivery system and drug-loading range are present.

The claim also does not expressly require intravitreal administration. Claim 2 adds vitreous placement as a narrower limitation.

How do the dependent claims narrow the patent scope?

Claim 2: vitreous placement

Claim 2 limits the method to placing the biodegradable system in the vitreous. This is commercially important because intravitreal implantation is the primary route for long-acting retinal corticosteroid delivery.

A product administered into the anterior chamber, subconjunctival space, or another ocular compartment would not satisfy claim 2, although it could remain within the scope of claim 1 if the system is placed in the eye and all other limitations are met.

Claim 3: PLGA polymer

Claim 3 specifies a polylactic acid-polyglycolic acid copolymer, commonly abbreviated PLGA. PLGA is widely used in biodegradable ocular implants because its degradation rate can be adjusted through polymer composition, molecular weight, particle dimensions, and end-group chemistry.

The claim does not specify:

The lactic-acid-to-glycolic-acid ratio
Polymer molecular weight
Implant geometry
Porosity
Manufacturing process
Release-rate profile
Whether the implant is a rod, microsphere, matrix, or another structure

A PLGA-based system with a different geometry or release profile could therefore fall within claim 3 if it satisfies the remaining limitations.

Claims 4 and 5: release duration

Claim 4 requires delivery for at least five days. Claim 5 requires delivery for at least about three weeks.

Claim 5 is commercially more significant because it targets sustained-release ocular implants rather than short-duration injections or rapidly dissolving inserts. The phrase "at least about 3 weeks" raises issues concerning experimental measurement, accepted release testing, and the point at which delivery is considered to occur.

A product releasing dexamethasone for several months would ordinarily satisfy a three-week minimum if the release is continuous or otherwise demonstrable during the claimed period.

Claim 6: dexamethasone

Claim 6 narrows the immunosuppressive agent to dexamethasone. It does not specify:

Dexamethasone base or a particular salt
Dose per implant
Particle size
Release kinetics
Therapeutic indication beyond the ocular edema requirement
Particular polymer chemistry

The claim can therefore reach multiple biodegradable dexamethasone delivery configurations if the 50%-80% loading range and other claim limitations are met.

What is the central limitation of US 9,283,178?

The 50%-80% drug-loading limitation is the central technical limitation.

A competing product may avoid the patent if the immunosuppressive agent is below 50% or above 80% of the total delivery-system weight. The calculation must use the total weight of the drug-delivery system, not merely the polymer matrix or the active portion of the implant.

For a formulation containing 0.7 mg dexamethasone, the relevant calculation is:

[ \text{Drug loading}=\frac{\text{weight of dexamethasone}}{\text{total weight of implant}}\times100 ]

If the implant weighs 1.0 mg and contains 0.7 mg dexamethasone, the drug loading is 70%. If the total implant weighs 2.0 mg, the loading is 35% and would fall outside the claimed range.

This limitation creates a potentially material design-around pathway. A generic or follow-on manufacturer could alter the polymer-to-drug ratio while preserving similar clinical performance.

Does the patent cover Ozurdex?

US 9,283,178 has a claim profile that is technically relevant to Ozurdex, the dexamethasone intravitreal implant marketed by AbbVie through its Allergan business.

Ozurdex uses dexamethasone in a biodegradable implant and is administered intravitreally for retinal conditions including macular edema associated with retinal vein occlusion and diabetic macular edema. The FDA-approved product contains a 0.7 mg dexamethasone implant and uses a biodegradable polymer system.[1]

Whether a particular Ozurdex product or authorized generic practices US 9,283,178 depends on the product's exact formulation, total implant weight, manufacturing specifications, and the asserted interpretation of the claim terms. The public label alone does not establish the precise total implant weight or the drug-loading percentage needed to determine literal infringement.

The patent is therefore best characterized as potentially relevant to the Ozurdex product class, not as conclusively covering every dexamethasone intravitreal implant.

What patents protect dexamethasone intravitreal implants?

The commercial patent estate for dexamethasone intravitreal implants is broader than US 9,283,178. Relevant patent categories include:

Patent category	Typical protected subject matter
Composition patents	Drug-polymer combinations and implant compositions
Method patents	Treating macular edema, diabetic macular edema, or retinal vein occlusion
Device patents	Implant geometry, applicators, and insertion systems
Release patents	Sustained delivery over defined periods
Manufacturing patents	Compression, extrusion, molding, coating, and sterilization
Formulation patents	Drug loading, polymer ratios, stabilizers, and excipients

US 9,283,178 is principally a method patent with composition-dependent limitations. It does not, based on the supplied claims, independently claim every dexamethasone implant, every PLGA implant, or every intravitreal steroid formulation.

When does US 9,283,178 lose exclusivity?

The patent issued on March 15, 2016. Its enforceable term depends on the patent-family priority chain, the filing date of the relevant nonprovisional application, any patent-term adjustment, and any patent-term extension.[2]

A patent's issue date is not the same as its expiration date. For a modern utility patent, the ordinary term is generally 20 years from the earliest effective nonprovisional filing date, subject to statutory adjustments.[3]

The patent's actual expiration should therefore be determined from:

The earliest effective nonprovisional priority date.
Continuation and divisional relationships.
Patent-term adjustment shown on the issued patent.
Any terminal disclaimer.
Any patent-term extension under 35 U.S.C. § 156.

The claims supplied do not establish those dates. An exact expiration date cannot be reliably stated from the claim text alone.

Is US 9,283,178 an Orange Book patent?

Orange Book listing is product-specific. A patent may be listed for an approved drug only if it claims the drug, a formulation or composition containing the drug, or an approved method of using the drug under FDA listing rules.[4]

A method claim directed to treating ocular edema may be eligible for listing if it reads on an FDA-approved use of the relevant dexamethasone product. The listing question cannot be resolved solely from the claims supplied because it requires comparison with:

The FDA-approved product
The approved indications
The patent-holder's submitted use codes
FDA's current Orange Book patent table
Any delisting, expiration, or challenge history

For Ozurdex, the relevant Orange Book analysis must distinguish US 9,283,178 from other patents covering the implant, delivery system, formulation, and approved uses. A product may remain blocked by other listed patents even if this patent is expired or successfully challenged.

What Paragraph IV risks does the patent create?

An ANDA applicant seeking approval for a generic version of a protected ophthalmic drug may address listed patents through a Paragraph IV certification. The applicant asserts that the patent is invalid, unenforceable, or will not be infringed.[5]

For US 9,283,178, likely Paragraph IV theories include:

Noninfringement

A generic applicant could argue that its product:

Contains less than 50% dexamethasone by total implant weight.
Uses more than 80% active agent.
Does not use a bioerodible polymer.
Does not use PLGA where claim 3 is asserted.
Does not deliver the agent for at least three weeks.
Is not used to treat ocular edema.
Is not placed in the vitreous, if only claim 2 is asserted.

Invalidity

Potential validity arguments would focus on:

Anticipation by earlier biodegradable ocular implants.
Obviousness based on PLGA steroid delivery systems.
Written-description support for the 50%-80% range.
Enablement of the full scope of immunosuppressive agents and ocular edema conditions.
Definiteness of terms such as "about," "bioerodible," and "delivers."

The strongest validity issue would likely involve the combination of known elements: intravitreal placement, dexamethasone, PLGA, sustained delivery, and high drug loading. The patent holder's response would depend on the prosecution record, experimental data, and evidence of release performance or clinical benefit.

What generic launch scenarios exist?

Scenario	Commercial consequence
Patent expires before approval	Launch may occur after approval if no other blocking patents remain
Paragraph IV certification with no litigation	FDA approval timing depends on regulatory exclusivity and certification mechanics
Suit filed within 45 days	Automatic stay can delay approval for up to 30 months, subject to statutory exceptions
Successful noninfringement position	Generic may launch without changing its formulation
Formulation design-around	Applicant may use a different loading percentage or polymer system
Settlement	Launch date depends on the negotiated agreement and antitrust constraints
Other patents remain enforceable	Generic may face a later launch despite defeating US 9,283,178

The practical risk is cumulative. A generic applicant must clear the entire relevant Orange Book estate, not merely this patent.

How strong is the patent estate?

US 9,283,178 has moderate claim breadth and potentially meaningful product relevance.

Strengths

Covers a commercially important treatment method.
Reaches a broad class of immunosuppressive agents in claim 1.
Captures vitreous placement through claim 2.
Specifically addresses PLGA through claim 3.
Includes a dexamethasone claim in claim 6.
Uses a drug-loading range that may correspond to certain high-load implants.

Weaknesses

The method claims require actual treatment of ocular edema.
The 50%-80% loading range creates a measurable design-around.
Claims 4 and 5 depend on proving release duration.
Claim 6 is limited to dexamethasone but remains subject to all claim 1 limitations.
The patent does not, from the supplied claims, cover non-biodegradable implants.
It does not necessarily cover formulations outside the loading range.
It does not independently claim the delivery applicator or manufacturing process.

The patent is stronger against a high-loading biodegradable dexamethasone implant than against a low-loading implant, a non-biodegradable system, or an injectable formulation that does not form the claimed delivery system.

How does the patent compare with competing ocular steroid products?

Product	Active agent	Delivery approach	Relevance to US 9,283,178
Ozurdex	Dexamethasone	Biodegradable intravitreal implant	Highest technical overlap
Iluvien	Fluocinolone acetonide	Non-biodegradable intravitreal implant	Generally outside PLGA limitation
Retisert	Fluocinolone acetonide	Non-biodegradable implant	Generally outside bioerodible-system scope
Yutiq	Fluocinolone acetonide	Non-biodegradable intravitreal implant	Generally outside claim 3
Injectable dexamethasone suspension	Dexamethasone	Conventional injection	May not satisfy delivery-system and polymer limitations

The patent is not a general monopoly over corticosteroid treatment of ocular edema. Its commercial scope is concentrated in biodegradable, sustained-release implants with specified active-agent loading.

What litigation and licensing issues matter?

A complete litigation assessment requires the USPTO continuity record, PACER docket review, FDA Orange Book history, and any settlement filings. The supplied claims alone do not establish whether US 9,283,178 has been asserted, challenged, licensed, disclaimed, or terminally disclaimed.

The relevant transaction structures would include:

License agreements covering biodegradable ophthalmic implants.
Co-development agreements for dexamethasone delivery systems.
Settlement agreements resolving Paragraph IV litigation.
Manufacturing licenses for PLGA implant technology.
Patent assignments within the Allergan or AbbVie corporate group.

A license to a broader implant platform does not necessarily grant freedom to operate under this patent. The agreement must be reviewed for field-of-use limits, geographic scope, sublicense rights, royalty triggers, and coverage of method claims.

What manufacturing and geographic barriers exist?

The key manufacturing barrier is not merely making a PLGA implant. The manufacturer must control:

Active-agent loading within the claimed range.
Uniformity across production lots.
Polymer degradation and release kinetics.
Sterility and particulate limits.
Implant dimensions and insertion performance.
Stability through shelf life.
Analytical methods capable of measuring total implant mass and active content.

The US patent protects only US conduct within its enforceable term. Separate foreign family members may apply in Europe, Canada, Japan, Australia, and other markets, but each jurisdiction requires an independent validity and expiry analysis. A US freedom-to-operate conclusion cannot be extended automatically to foreign markets.

Key Takeaways

US 9,283,178 is a method patent directed to treating ocular edema with a bioerodible ocular delivery system.
Claim 1 requires 50%-80% immunosuppressive-agent loading by total system weight.
Claim 2 covers vitreous placement.
Claim 3 specifically covers PLGA.
Claims 4 and 5 require delivery for at least five days or about three weeks.
Claim 6 specifically covers dexamethasone.
The patent has its greatest potential relevance to high-loading biodegradable dexamethasone intravitreal implants such as the Ozurdex product class.
The 50%-80% range is both a source of commercial coverage and a potential design-around.
Exact expiration, Orange Book status, litigation history, and settlement status require review of the patent record, FDA listings, and court dockets.
A generic applicant must address this patent together with the broader product-specific patent estate.

FAQs About US Patent 9,283,178

Does US 9,283,178 cover all intravitreal dexamethasone products?

No. The product must use a bioerodible delivery system and satisfy the 50%-80% drug-loading requirement, with additional limitations applying to PLGA, release duration, vitreous placement, or dexamethasone.

Can a competitor avoid the patent by using fluocinolone acetonide?

Potentially, but changing the active agent alone may not resolve every issue. Claim 1 covers an immunosuppressive agent broadly, while claim 6 is limited to dexamethasone. The alternative product must still be evaluated against claim 1.

Does a non-biodegradable ocular implant fall within claim 3?

No, claim 3 requires a bioerodible polymer comprising PLGA. A non-biodegradable implant would generally not satisfy that limitation, although claim 1 must be analyzed separately.

Does a product releasing drug for six months satisfy the three-week limitation?

Ordinarily, sustained delivery for six months would meet a minimum-duration limitation of at least about three weeks, assuming the product satisfies the other claim elements.

Is US 9,283,178 enough by itself to block a generic Ozurdex launch?

No. Generic launch risk depends on the full Orange Book-listed patent estate, regulatory exclusivity, litigation, settlement terms, and the generic product's exact formulation and approved labeling.

References

U.S. Food and Drug Administration. (n.d.). Ozurdex (dexamethasone intravitreal implant) prescribing information.
United States Patent and Trademark Office. (2016). U.S. Patent No. 9,283,178.
35 U.S.C. §§ 154, 156.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
21 U.S.C. § 355(j)(2)(A)(vii)(IV); 35 U.S.C. § 271(e)(2).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	306951	⤷ Start Trial
Australia	2002236495	⤷ Start Trial
Australia	2006201271	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,283,178

Summary for Patent: 9,283,178